Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis
Authors
Keywords
-
Journal
INFLAMMOPHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-22
DOI
10.1007/s10787-022-00933-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
- (2020) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- (2019) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
- (2019) Atul Deodhar et al. LANCET
- Immune cells involved in the pathogenesis of ankylosing spondylitis
- (2018) Alireza Rezaiemanesh et al. BIOMEDICINE & PHARMACOTHERAPY
- The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: New insights and updates
- (2018) Farhad Babaie et al. IMMUNOLOGY LETTERS
- IL-17 in the immunopathogenesis of spondyloarthritis
- (2018) Leonie S. Taams et al. Nature Reviews Rheumatology
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
- (2018) Mitsumasa Kishimoto et al. Modern Rheumatology
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
- (2018) Jürgen Braun et al. RHEUMATOLOGY
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
- (2017) H. Marzo-Ortega et al. ARTHRITIS CARE & RESEARCH
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
- (2016) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- The roles and functional mechanisms of interleukin-17 family cytokines in mucosal immunity
- (2016) Xinyang Song et al. Cellular & Molecular Immunology
- Primary immune deficiencies with defects in neutrophil function
- (2016) M. C. Dinauer Hematology-American Society of Hematology Education Program
- Characterization of Lamprey IL-17 Family Members and Their Receptors
- (2015) Q. Han et al. JOURNAL OF IMMUNOLOGY
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
- (2014) M. A. Puhan et al. BMJ-British Medical Journal
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis
- (2012) Wei-Sheng Chen et al. Journal of the Chinese Medical Association
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- Mechanisms controlling Th17 cytokine expression and host defense
- (2011) Jeremy P. McAleer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
- (2011) A. Puel et al. SCIENCE
- Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
- (2011) Heiner Appel et al. ARTHRITIS RESEARCH & THERAPY
- The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
- (2010) M. Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
- (2009) M Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis
- (2009) Heather R. Conti et al. JOURNAL OF EXPERIMENTAL MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation